Albert Abad

5.5k total citations · 1 hit paper
84 papers, 4.2k citations indexed

About

Albert Abad is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Albert Abad has authored 84 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 18 papers in Pathology and Forensic Medicine. Recurrent topics in Albert Abad's work include Colorectal Cancer Treatments and Studies (50 papers), Cancer Treatment and Pharmacology (27 papers) and Gastric Cancer Management and Outcomes (16 papers). Albert Abad is often cited by papers focused on Colorectal Cancer Treatments and Studies (50 papers), Cancer Treatment and Pharmacology (27 papers) and Gastric Cancer Management and Outcomes (16 papers). Albert Abad collaborates with scholars based in Spain, United States and Italy. Albert Abad's co-authors include J Maestre, Eva Martinez‐Balibrea, Anna Martínez‐Cardús, José Luís Zamora Manzano, Rafael Rosell, Aurelio Ariza, R. Rosell, Agustí Barnadas, Mercedes Canela and Carlos Camps and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Albert Abad

79 papers receiving 4.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer

1994 923 citations R. Rosell, José Gómez‐Codina et al. New England Journal of Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Albert Abad	2.5k	1.6k	1.2k	565	489	84	4.2k
Ralph Levitt	2.1k 0.9×	892 0.6×	670 0.6×	273 0.5×	682 1.4×	67	3.6k
Chiara Carlomagno	3.4k 1.4×	1.1k 0.7×	1.0k 0.9×	1.2k 2.1×	679 1.4×	99	4.7k
Renuka Iyer	1.5k 0.6×	753 0.5×	573 0.5×	460 0.8×	755 1.5×	178	3.0k
Scott N. Holden	2.2k 0.9×	860 0.5×	1.3k 1.1×	424 0.8×	176 0.4×	44	3.7k
Sergio Ricci	2.7k 1.1×	1.2k 0.8×	971 0.8×	592 1.0×	1.9k 3.9×	62	5.5k
Karen Borgonovo	2.7k 1.1×	1.5k 0.9×	545 0.5×	639 1.1×	667 1.4×	83	3.8k
Jong Seok Lee	3.4k 1.4×	3.6k 2.3×	1.1k 0.9×	684 1.2×	593 1.2×	144	5.2k
Dolores Isla	3.1k 1.2×	3.1k 1.9×	1.5k 1.2×	888 1.6×	624 1.3×	202	5.1k
Naureen Starling	3.8k 1.5×	2.7k 1.7×	1.2k 1.0×	986 1.7×	1.6k 3.2×	171	6.2k
Stefania Mosconi	1.6k 0.6×	648 0.4×	333 0.3×	422 0.7×	665 1.4×	40	2.3k

Countries citing papers authored by Albert Abad

Since Specialization

Citations

This map shows the geographic impact of Albert Abad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Abad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Abad more than expected).

Fields of papers citing papers by Albert Abad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Abad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Abad. The network helps show where Albert Abad may publish in the future.

Co-authorship network of co-authors of Albert Abad

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Abad. A scholar is included among the top collaborators of Albert Abad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Abad. Albert Abad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Abad, Albert, et al.. (2025). The Air-Test score for prediction of postoperative pulmonary complications after general anaesthesia: analysis of harmonised trial data and a prospective observational cohort. British Journal of Anaesthesia. 136(2). 716–723.

Benavides, Manuel, Auxiliadora Gómez‐España, Pilar García‐Alfonso, et al.. (2021). Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). European Journal of Surgical Oncology. 48(5). 1123–1132. 3 indexed citations

García‐Alfonso, Pilar, Eduardo Díaz‐Rubio, Albert Abad, et al.. (2021). First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis. Drugs & Aging. 38(3). 219–231. 4 indexed citations

Abad, Albert, Eva Martinez‐Balibrea, José María Viéitez, et al.. (2017). Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. Annals of Oncology. 29(2). 439–444. 11 indexed citations

Porras, Vicenç Ruiz de, Sara Bystrup, Anna Martínez‐Cardús, et al.. (2016). Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway. Scientific Reports. 6(1). 24675–24675. 113 indexed citations

Capdevila, Jaume, Ramón Salazar, Irene Halperín, Albert Abad, & James C. Yao. (2011). Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer and Metastasis Reviews. 30(S1). 27–34. 37 indexed citations

Aranda, Enrique, Albert Abad, Alfredo Carrato, et al.. (2011). Treatment recommendations for metastatic colorectal cancer. Clinical & Translational Oncology. 13(3). 162–178. 21 indexed citations

Abad, Albert. (2008). New drugs in the treatment of gastric tumors. Clinical & Translational Oncology. 10(5). 256–261. 6 indexed citations

Abad, Albert, Joan Figueras, Cristina Valls, et al.. (2007). Guidelines for the detection and treatment of liver metastases of colorectal cancer. Clinical & Translational Oncology. 9(11). 723–730. 7 indexed citations

10.

Abad, Albert, Alfredo Carrato, Matilde Navarro, et al.. (2005). Two Consecutive Phase II Trials of Biweekly Oxaliplatin plus Weekly 48-Hour Continuous Infusion of Nonmodulated High-Dose 5-Fluorouracil as First-Line Treatment for Advanced Colorectal Cancer. Clinical Colorectal Cancer. 4(6). 384–389. 7 indexed citations

11.

Font, Albert, José Miguel Sánchez, Miquel Tarón, et al.. (2003). Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Investigational New Drugs. 21(4). 435–443. 48 indexed citations

12.

Font, Albert, José Miguel Sánchez, Rafael Rosell, et al.. (2002). Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Lung Cancer. 37(2). 213–218. 17 indexed citations

13.

Plasencia, Carmen, et al.. (2000). Cytotoxic Effects of Topotecan Combined with Various Active G2/M-Phase Anticancer Drugs in Human Tumor-Derived Cell Lines. Investigational New Drugs. 18(2). 139–148. 37 indexed citations

14.

Alcalde, Juan, et al.. (1999). Carcinoma coloide de mama. Nuestra experiencia.. Revista de Senología y Patología Mamaria. 12(1). 3–6. 1 indexed citations

15.

Machover, D., Eduardo Díaz‐Rubio, Aimery de Gramont, et al.. (1996). Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Annals of Oncology. 7(1). 95–98. 331 indexed citations

16.

Piedbois, Pascal, Marc Buyse, G.H. Blijham, et al.. (1994). Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Journal of Clinical Oncology. 12(5). 960–969. 162 indexed citations

17.

Rosell, Rafael, Albert Font, Aurelio Ariza, et al.. (1994). K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma. Lung Cancer. 11(1-2). 19–27. 27 indexed citations

18.

Rosell, R., José Gómez‐Codina, Carlos Camps, et al.. (1994). A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer. New England Journal of Medicine. 330(3). 153–158. 923 indexed citations breakdown →

19.

Abad, Albert, et al.. (1991). 5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors. Annals of Oncology. 2(2). 153–153. 1 indexed citations

20.

Abad, Albert, Rafael Rosell, M.C. Pastor, et al.. (1991). Sequential Combination of Methotrexate (MTX), 5-Fluorouracil (FU), and High-Dose Folinic Acid (FA) in Advanced Colorectal Cancer. American Journal of Clinical Oncology. 14(5). 393–396. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact